<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436889</url>
  </required_header>
  <id_info>
    <org_study_id>14-15553</org_study_id>
    <nct_id>NCT02436889</nct_id>
  </id_info>
  <brief_title>Treatment of Incontinence Without Memory Problems</brief_title>
  <acronym>TRIUMPH</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An 8-week randomized, controlled, pilot clinical trial of Mirabegron compared to a standard
      anticholinergic therapy (Detrol LA) in elderly women with urgency urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Who Completed and Discontinued the Study</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Feasibility - Assessment of retention rates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Range of 0-80, with the higher the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Trail Making Test, Trail A Time, Range 0-150 seconds, Lower score indicates better functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Physical function/mobility, Range 0-12, the higher the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Study participants record number of urinary incontinence episodes in a voiding diary. The total urinary incontinence frequency is the sum of urinary incontinence episodes per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The sum of urge type incontinence episodes reported by participants on a voiding diary per day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Urge Incontinence</condition>
  <condition>Urinary Incontinence, Urge</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine Tartrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <arm_group_label>Mirabegron</arm_group_label>
    <other_name>Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine Tartrate</intervention_name>
    <arm_group_label>Tolterodine Tartrate</arm_group_label>
    <other_name>Detrol LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Community-dwelling, ambulatory females ≥ 65 years old

          -  Urgency or Mixed Urgency Predominate Urinary Incontinence (subject-reported) for ≥ 3
             months prior to Screening (Visit 1)

          -  On a 3-day voiding diary, documentation of at least 3 urgency incontinence episodes
             with the number of urgency incontinence episodes greater than number of stress
             incontinence episodes

          -  Capability of understanding and having signed the informed consent form after full
             discussion of the research nature of the treatment and its risk and benefits

          -  Ability to perform all procedures and tests required by the protocol

          -  Report having a primary health care provider

          -  Willingness to remain on stable medication regime for duration of the randomized
             controlled trial. Participants will be asked to not add new medications during the
             randomized controlled trial, such as diuretics and other medications which may affect
             their voiding pattern.

        Exclusion Criteria:

          -  Seated blood pressure &gt;180/110 at Screening or Baseline

          -  Physician diagnosis of dementia

          -  Current use of dementia medications, debilitating or recent neurologic disease

          -  Mini Mental State Examination (MMSE) score &lt;20

          -  History of urinary retention, gastric retention, uncontrolled narrow angle glaucoma,
             myasthenia gravis, severe ulcerative colitis, toxic megacolon, fistula or a hole in
             your bladder or rectum, birth defect leading to urine leakage, and urine leakage
             starting in childhood

          -  Clinically significant hepatic (Child Pugh B or greater) or renal (creatinin clearance
             &lt;30 mL/min or eGFR &lt;30 mL/min/1.73 m2)

          -  Neurologic conditions such as stroke, multiple sclerosis, spinal cord injury, or
             Parkinson's disease.

          -  Major cardiovascular even in the past 6 months (i.e., MI, unstable angina,
             hospitalization for chest pain)

          -  Symptomatic pelvic organ prolapse defined as participant report of feeling or seeing a
             bulge outside the vagina within the past 3 months.

          -  History of surgery for incontinence in the past 5 years, pelvic surgery the past 6
             months (i.e., for prolapse or hysterectomy), intra-vesical therapy (botox), and/or
             bulk injections within the past 6 months.

          -  A known history of interstitial cystitis or a significant pain component associated
             with OAB symptoms, uninvestigated hematuria, urogenital cancer, radiation to the
             pelvis or external genitalia.

          -  Urinary tract infection (UTI) as shown by the results of the urinalysis at screening
             or recurrent urinary tract infection (RUTIs) defined as treatment for UTI &gt;3 times in
             the last year.

          -  Urinary retention (post-void residual urine volume &gt;150 cc measured by Bladder scan at
             screening.

          -  Use of any electrostimulation, bladder training, or pelvic floor exercises (with
             certified incontinence practitioners) within 4 weeks of Screening.

          -  Received study medication in any previous mirabegron clinical trial.

          -  Prior failure for either efficacy or tolerability of ≥ 2 OAB medications in the last
             year. (Failure: inadequate symptom control after two medications for a minimum of one
             month each.)

          -  Has been treated within 2 weeks prior to Screening and/or is currently being treated
             with:

               -  Any drug treatment for OAB

               -  Any drugs with significant anticholinergic and antispasmodic effects (see
                  exception for tricyclic antidepressants below)

          -  Has started treatment with tricyclic antidepressants or estrogens within 4 weeks prior
             to Screening and/or is not on a stable dose.

          -  Intermittent use or unstable dose of diuretics. Treatment with diuretics initiated
             within 2 weeks prior to baseline and/or is not on a stable dose is not permitted.

          -  Treatment with potent CYP3A4 inhibitors, such as clarithromycin, ketoconazole, and
             itraconazole within 2 weeks prior to Screening.

          -  Administration of medications capable of inducing hepatic enzyme metabolism or
             transport (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or St.
             John's Wort) in the past 30 days.

          -  Administration of narrow therapeutic index drugs metabolized by CYP2D6, such as
             thioridazine, flecainide, and propafenone.

          -  Previously received any investigational drug within 30 days prior to trial entry.

          -  Alcohol and/or any other drug abuse in the opinion of the investigator.

          -  Participants who have any medical (including known history of major hematological,
             renal, cardiovascular, or hepatic abnormalities) or psychological condition or social
             circumstances that would impair their ability to participate reliably in the trial, or
             those who may increase the risk to themselves or others by participating.

          -  Participants who, in the opinion of the investigator, are not likely to complete the
             trial for whatever reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslee Subak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <results_first_submitted>March 5, 2019</results_first_submitted>
  <results_first_submitted_qc>March 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Alison Huang, MD</investigator_full_name>
    <investigator_title>Associate Professor, Department of General Internal Medicne; Epidemiology &amp; Biostatistics; Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02436889/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mirabegron</title>
          <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
        </group>
        <group group_id="P2">
          <title>Tolterodine Tartrate</title>
          <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No improvement in symptoms</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does not like/could not tolerate medicat</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mirabegron</title>
          <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
        </group>
        <group group_id="B2">
          <title>Tolterodine Tartrate</title>
          <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>65-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian or Asian American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incontinence Frequency</title>
          <description>Urinary incontinence refers to any involuntary leakage of urine. Urge incontinence (also known as urgency incontinence) refers to involuntary leakage of urine that occurs as a result of a sudden or strong urge to urinate, when an individual cannot reach the toilet in time)</description>
          <units>Episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total Urge Incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.87" spread="2.33"/>
                    <measurement group_id="B2" value="4.48" spread="1.92"/>
                    <measurement group_id="B3" value="4.16" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Urinary Incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.43" spread="3.20"/>
                    <measurement group_id="B2" value="4.96" spread="1.98"/>
                    <measurement group_id="B3" value="4.68" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>California Verbal Learning Test</title>
          <description>The California Verbal Learning Test involves the presentation of one list of 16 words taken from three categories. Following a brief delay, the participant is asked to recall the words. Memory is then tested after another 20-minute delay. Trials 1-5 free recall is the total number of correctly remembered items (for trials 1-5). This would make the possible range for this score 0-80, with a higher score being better.</description>
          <units>Trials 1-5 Free Recall Total</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.36" spread="12.29"/>
                    <measurement group_id="B2" value="49.50" spread="10.98"/>
                    <measurement group_id="B3" value="50.48" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Physical Performance Battery</title>
          <description>Range 0-12, higher score indicates better functioning.</description>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.67" spread="2.1"/>
                    <measurement group_id="B2" value="11.00" spread="2.2"/>
                    <measurement group_id="B3" value="10.83" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trail Making Test</title>
          <description>These are timed, written tests with shorter test times corresponding to better attention, visual scanning, and executive function.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trail A Time (0-150 sec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.33" spread="26.3"/>
                    <measurement group_id="B2" value="35.06" spread="9.5"/>
                    <measurement group_id="B3" value="37.81" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail B Time (0-300 sec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.03" spread="61.5"/>
                    <measurement group_id="B2" value="85.39" spread="29.4"/>
                    <measurement group_id="B3" value="89.38" spread="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Instrumental Activities of Daily Living</title>
          <description>Range 0-8, higher the score indicates better functioning.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.83" spread="0.4"/>
                    <measurement group_id="B2" value="7.91" spread="0.3"/>
                    <measurement group_id="B3" value="7.87" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Completed and Discontinued the Study</title>
        <description>Feasibility - Assessment of retention rates.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
          </group>
          <group group_id="O2">
            <title>Tolterodine Tartrate</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Completed and Discontinued the Study</title>
          <description>Feasibility - Assessment of retention rates.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Completed study</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discontinued Early</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks</title>
        <description>Range of 0-80, with the higher the score the better.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
          </group>
          <group group_id="O2">
            <title>Tolterodine Tartrate</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks</title>
          <description>Range of 0-80, with the higher the score the better.</description>
          <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" lower_limit="1.13" upper_limit="8.27"/>
                    <measurement group_id="O2" value="1.59" lower_limit="-2.20" upper_limit="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2415</p_value>
            <method>ANCOVA</method>
            <method_desc>change from baseline, adjusted for baseline value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.09</ci_lower_limit>
            <ci_upper_limit>8.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks</title>
        <description>Trail Making Test, Trail A Time, Range 0-150 seconds, Lower score indicates better functioning</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
          </group>
          <group group_id="O2">
            <title>Tolterodine Tartrate</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks</title>
          <description>Trail Making Test, Trail A Time, Range 0-150 seconds, Lower score indicates better functioning</description>
          <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.34" lower_limit="-15.57" upper_limit="-7.11"/>
                    <measurement group_id="O2" value="0.67" lower_limit="-3.79" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.16</ci_lower_limit>
            <ci_upper_limit>-5.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks</title>
        <description>Physical function/mobility, Range 0-12, the higher the score the better.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
          </group>
          <group group_id="O2">
            <title>Tolterodine Tartrate</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks</title>
          <description>Physical function/mobility, Range 0-12, the higher the score the better.</description>
          <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-1.03" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.24" lower_limit="-0.47" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1956</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks</title>
        <description>Study participants record number of urinary incontinence episodes in a voiding diary. The total urinary incontinence frequency is the sum of urinary incontinence episodes per day.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
          </group>
          <group group_id="O2">
            <title>Tolterodine Tartrate</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks</title>
          <description>Study participants record number of urinary incontinence episodes in a voiding diary. The total urinary incontinence frequency is the sum of urinary incontinence episodes per day.</description>
          <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" lower_limit="-3.10" upper_limit="-0.99"/>
                    <measurement group_id="O2" value="-3.91" lower_limit="-5.02" upper_limit="-2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0168</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks.</title>
        <description>The sum of urge type incontinence episodes reported by participants on a voiding diary per day.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
          </group>
          <group group_id="O2">
            <title>Tolterodine Tartrate</title>
            <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks.</title>
          <description>The sum of urge type incontinence episodes reported by participants on a voiding diary per day.</description>
          <population>Although 21 participants completed week 8 visits in some form, some participants declined to complete or had missing data for one or more outcome measures at this timepoint.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" lower_limit="-2.73" upper_limit="-0.54"/>
                    <measurement group_id="O2" value="-3.74" lower_limit="-4.90" upper_limit="-2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0101</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 8</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mirabegron</title>
          <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
Mirabegron</description>
        </group>
        <group group_id="E2">
          <title>Tolterodine Tartrate</title>
          <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
Tolterodine Tartrate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Stye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold/flu</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory problems/confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bladder Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Huang, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-514-8697</phone>
      <email>alison.huang@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

